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92 The Journal of Thoracic and Cardiobjective: Statin therapy in ambulatory populations is associated with a signif-
cant reduction in adverse cardiovascular events, including death and myocardial
nfarction. Much less is known about the beneficial effects of statins on acute
erioperative cardiovascular events. The purpose of this study was to determine
hether preoperative statin therapy is associated with a reduced risk of early
ardiac death or nonfatal, in-hospital postoperative myocardial infarction after
rimary, elective coronary artery bypass graft surgery requiring cardiopulmo-
ary bypass.
ethods: The Multicenter Study of Perioperative Ischemia (McSPI) Epidemiology
I Study was a prospective, longitudinal study of 5436 patients undergoing coronary
rtery bypass graft surgery between November 1996 and June 2000 at 70 centers in
7 countries. The present study consisted of a pre-specified subset of these subjects
ivided into patients receiving (n  1352) and not receiving (n  1314) preoper-
tive statin therapy. To control for potential bias related to use of statin therapy, the
tudy estimated propensity scores by logistic regression to determine the predicted
robability of inclusion in the “statin” group. Multivariate, stepwise logistic regres-
ion was then performed, controlling for patient demographics, medical history,
perative characteristics, and propensity score to determine whether preoperative
tatin therapy was independently associated with a reduction in the risk of early
DOS-POD3) cardiac death and/or nonfatal, in-hospital postoperative myocardial
nfarction.
esults: Preoperative statin therapy was independently associated with a signif-
cant reduction (adjusted odds ratio [OR] 0.25; 95% confidence intervals [CI]
.07-0.87) in the risk of early cardiac death after primary, elective coronary
ypass surgery (0.3% vs 1.4%; P  .03), but was not associated with a reduced
isk of postoperative nonfatal, in-hospital myocardial infarction (7.9% vs 6.2%;
 not significant). Discontinuation of statin therapy after surgery was indepen-
ently associated with a significant increase in late (POD4-discharge) all-cause
ortality (adjusted OR 2.64; 95% CI 1.32-5.26) compared with continuation of
tatin therapy (2.64% vs 0.60%; P  .01). This was true even when controlling for
he postoperative discontinuation of aspirin, -blocker, or angiotensin-converting
nzyme inhibitor therapy. Discontinuation of statin therapy after surgery was also
ndependently associated with a significant increase in late cardiac mortality (ad-
usted OR 2.95; 95% CI 1.31-6.66) compared with continuation of statin therapy
1.91% vs 0.45%; P  0.01).
onclusions: Preoperative statin use is associated with reduced cardiac mortality
fter primary, elective coronary artery bypass grafting. Postoperative statin discon-
inuation is associated with increased in-hospital mortality. Although further ran-
omized trials are needed to confirm these findings, these data suggest the impor-
ance of perioperative statin administration.
vascular Surgery ● August 2006
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Collard et al Surgery for Acquired Cardiovascular Diseasedministration of 3-hydroxy-3-methylglutaryl coen-
zyme A (HMG-CoA) inhibitors or “statins” to am-
bulatory patients reduces low-density lipoprotein
LDL), total cholesterol levels, and the risk of adverse
ardiovascular events, including death, myocardial infarc-
ion (MI), and stroke.1-11 Moreover, the beneficial effects 
tatin therapy are not limited to patients with hypercholes-
erolemia. Even in patients with normal total and LDL
holesterol levels, long-term statin administration reduces
he incidence of adverse cardiovascular outcomes and de-
reases the need for coronary angioplasty or coronary artery
ypass graft (CABG) surgery.4-6
Although the mechanisms by which statins reduce cardio-
ascular events have yet to be fully elucidated, statins have
everal important, non–lipid-mediated effects. For example,
he metabolite of HMG-CoA reductase, mevalonic acid, is a
recursor of the cholesterol and the isoprenoid intermediates,
arnesyl and geranylgeranyl pyrophosphate, which are essen-
ial for the posttranslational modification of intracellular G-
roteins that regulate endothelial, platelet, and leukocyte func-
ion.12 Statins have also been shown to modulate vasc
emodeling through inhibition of cellular matrix metallopro-
eases and transcription factors, such as nuclear factor-B.12
hus, statins exert pleiotropic effects, independent of cho-
esterol reduction, that result in direct antiatherosclerotic,
ntithrombotic, and anti-inflammatory properties.12-14
In contrast to the widely described long-term benefits of
tatins in ambulatory patients, much less is known about the
ffects of statins on acute postoperative cardiovascular
vents.14-18 Recently, statins were shown to be indep-
ently associated with a reduced risk of postoperative mor-
ality in patients undergoing major, noncardiac vascular
urgery.15 Further, preoperative statin therapy has been -
ependently associated with a significant reduction in the
isk of all-cause mortality in patients undergoing CABG
urgery.16,17 The aim of the current study was to determ
hether preoperative statin therapy is independently asso-
iated with a reduced incidence of early (date of surgery–
ostoperative day 3 [DOS-POD3]) cardiac death or nonfa-
al, in-hospital postoperative MI using the international
ulticenter Study of Perioperative Ischemia (McSPI) Epi-
emiology II Study of patients undergoing primary, elec-
ive CABG surgery.18 Additionally, we hypothesized tha
iscontinuation of statins in the postoperative period is
ndependently associated with an increased risk of late
POD4-discharge), in-hospital cardiac mortality, even when
ontrolling for the discontinuation of preoperative aspirin
-blocker, or angiotensin-converting enzyme (ACE) inhib-
tor therapy.
ethods
tudy Design
he McSPI Epidemiology II Study was prospective and longitu-
inal, consisting of 5436 patients with coronary artery disease b
The Journal of Thoraciccheduled to undergo CABG surgery with the use of cardiopul-
onary bypass (CPB) at one of 70 medical institutions in 17
ountries in North America, South America, Europe, the Middle
ast, and Asia. Enrollment began in November 1996 and ended in
une 2000.18 After institutional review board approval and writ
nformed consent had been obtained from each patient, 100 pa-
ients were prospectively enrolled at each institution according to
 systematic sampling scheme.18 Patients were excluded from t
resent analysis if they (1) underwent emergency or urgent CABG
urgery (n  952); (2) had repeat CABG surgery (n  306); or (3)
ad CABG surgery with concomitant valve or other cardiac sur-
ery (n  827). Additionally, patients were excluded (n  685)
rom the present analysis for the following reasons: had a known
istory of hepatitis B or C, cancer, hematologic disorder, previous
rgan transplantation, alcohol or intravenous drug abuse, religious
eliefs precluding transfusion, prior chemotherapy or immuno-
uppressive therapy; were currently HIV seropositive; pregnant,
r had some other extraordinary characteristic (eg, history of
epression, mental illness, associated cardiac anomalies, or severe
ortic, thromboembolic, or neurologic disease). After application
f the exclusion criteria, the remaining patients (n  2666) were
lassified into 2 groups: patients receiving preoperative statin
herapy (n  1352) and patients not receiving any preoperative
ntihyperlipidemic therapy (n  1314) at the time of admissio
ommercially available statins screened for in this study included
erivastatin, fluvastatin, simvastatin, atorvastatin, lovastatin, and
ravastatin.
tudy Data
ata on more than 7500 variables, including patient demographics,
reoperative risk factors, and the incidence of adverse postopera-
ive outcomes, were collected on each enrolled patient by inde-
endent investigators during the course of the hospitalization for
he CABG surgery (the index hospitalization). Data were adjudi-
ated centrally (IREF, San Francisco, Calif), with all data for each
atient examined for completeness and accuracy before the data-
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme 4
ACS  acute coronary syndromes
CABG  coronary artery bypass graft
CI  confidence intervals
CPB  cardiopulmonary bypass
DOS  date of surgery
HMG-CoA 3-hydroxy-3-methylglutaryl coenzyme A
IREF  Ischemia Research and Education
Foundation
LDL  low-density lipoprotein
McSPI Multicenter Study of Perioperative
Ischemia
MI myocardial infarction
MIRACL Myocardial Ischemia Reduction with
Acute Cholesterol Lowering
OR  odds ratios
POD  postoperative dayase was closed.
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3easurement of Outcomes
ll outcomes were pre-specified, defined by the protocol, and
djudicated by investigators at each site who were unaware of
reatment-group assignment. Cardiac death was defined as death
ccurring secondary to an MI, heart failure, or arrhythmia. A
iagnosis of MI was made if there were new Q waves (Minnesota
ode 1-1-1 to 1-2-7), new persistent ST-segment or T-wave
hanges (Minnesota code 4-1, 4-2, 5-1, 5-2, or 9-2) and elevated
alues for the myocardial band isoenzyme of creatine kinase, or
vidence of acute MI at autopsy.18 A diagnosis of heart failure w
ade if a ventricular assist device was used, if continuous inotro-
ic support was required for at least 24 hours, or if there was
vidence of heart failure on autopsy.18 “Early” death was define
s death occurring in hospital between DOS-POD3. “Late” death
as defined as death occurring in hospital between POD4-
ischarge.
tatistical Analysis
tatistical analyses were performed with SAS, version 8.12 (SAS
nstitute, Cary, NC). Patients’ preoperative and intraoperative de-
ographics, risk factors, and medications were first compared
etween groups by univariate (2) analysis (Tables 1 and 2). To
ontrol for selection bias related to statin use, the study estimated
propensity score for each patient using unconditional logistic
egression to determine the predicted probability of inclusion in
he preoperative “statin” group. Variables used to determine the
ropensity score included age, gender, ethnicity, body mass index,
ducational level, tobacco use, medications, and preoperative his-
ory of diabetes, hypercholesterolemia, cardiovascular, renal, neu-
ologic, or hematologic disease. The propensity score and all
redictor variables significant at a 2-tailed nominal P  .15 in the
nivariate analysis were then entered into a multivariate stepwise
ogistic regression model to determine whether preoperative statin
herapy was independently associated with a reduction in the risk
f early cardiac death or nonfatal, in-hospital postoperative MI
fter primary, elective CABG surgery. Only those variables sig-
ificant at a 2-tailed nominal P  .05 were retained within the
odel. To ascertain the effect of postoperative statin discontinu-
tion on late, in-hospital mortality, multivariate analysis was also
erformed as described above on the group of patients who re-
eived preoperative statin therapy, comparing patients in whom
tatin therapy was discontinued with those in whom it was not.
dds ratios (OR) and corresponding 95% confidence intervals (CI)
re reported, with associated P values.
esults
atient preoperative and intraoperative demographics are
resented in Tables 1 and 2, respectively. Patients recei
reoperative statin therapy were significantly more likely to
ave a history of hyperlipidemia (P  .001), smoking (P 
01), coronary stent placement (P .002), and percutaneous
ransluminal coronary angioplasty (P  .001) than were
atients not receiving preoperative antihyperlipidemia ther-
py. Additionally, significant differences in statin usage
etween geographic regions were observed (Table 1).
The incidence of all-cause mortality, cardiac mortality,
nd in-hospital MI is presented in Figure 1. Multivariatei
94 The Journal of Thoracic and Cardiovascular Surgery ● Augunalysis, including controlling for propensity score, showed
hat preoperative statin therapy was independently associ-
ted with a significant reduction in the risk of early all-cause
ortality (P  .04) and cardiac death (P  .04) after
lective, primary CABG surgery requiring CPB (Figure
ote that all early (DOS–POD3) deaths were cardiac in
rigin. Other significant independent predictors of early
ll-cause mortality (A) and cardiac mortality (B) are shown
n Figure 2. Preoperative statin therapy was not inde
ently associated with a significant reduction in the risk of
onfatal, in-hospital MI (P  .08). Only preoperative hep-
rin or warfarin use was found to be a significant, indepen-
ent predictor of postoperative nonfatal, in-hospital MI
P  .01). No significant differences between the commer-
ially available statins were observed with respect to the
ncidence of all-cause mortality, cardiac mortality, and in-
ospital MI.
Although preoperative statin therapy was independently
ssociated with a significant reduction in the risk of early
DOS-POD3) cardiac death, the incidence of all-cause,
n-hospital (DOS-discharge) mortality did not significantly
iffer between groups (1.9% vs 2.4%; P  not significant).
owever, multivariate analysis controlling for the postop-
rative discontinuation of preoperative statin, aspirin,
-blocker, or ACE inhibitor therapy revealed that discon-
inuation of statin therapy was independently associated
ith an increased risk of late (POD4-discharge) in-hospital
ll-cause mortality compared with continuation of statins
ostoperatively (2.64% vs 0.6%; P  .01; Figure 3). Sim
larly, discontinuation of statin therapy was independently
ssociated with an increased risk of late in-hospital cardiac
ortality compared continuation of statins postoperatively
1.91% vs 0.45%; P  .01; Figure 3). In contrast, disco
inuation of preoperative aspirin, -blocker, or ACE inhib-
tor therapy was not independently associated with an in-
reased risk of late, in-hospital all-cause mortality (Note
hat postoperative discontinuation of aspirin bordered on
ignificance; P  .054).
iscussion
hese data suggest that preoperative statin therapy is
ndependently associated with a reduced risk of early
DOS-POD3) cardiac mortality after elective, primary CABG
urgery requiring CPB, even after adjusting for patient
emographics, risk factors, medications, and statin propen-
ity score. Moreover, discontinuation of statin therapy in the
mmediate postoperative period is independently associated
ith an increased risk of late (POD4-discharge), all-cause
n-hospital mortality, even after adjusting for the postoper-
tive discontinuation of preoperative -blocker, aspirin, and
CE inhibitor therapy. Preoperative statin therapy is not
ndependently associated with a reduced risk of nonfatal,
n-hospital postoperative MI, whereas it is associated with
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Collard et al Surgery for Acquired Cardiovascular DiseaseABLE 1. Preoperative demographic variables and risk factors in patients receiving preoperative statin therapy and
atients not receiving preoperative antihyperlipidemic therapy
atient demographics and preoperative risk factors
%, [n])
No statin therapy
(n  1314)
Statin therapy
(n  1352) P value
ge (y) 63.4 0.26 61.9 0.26 .001
emale gender 18 (232) 19 (263) .23
ollege graduate 18 (238) 18 (245) .99
ody mass index 27.1 0.12 27.5 0.11 .04
iabetes mellitus type I 8 (102) 7 (98) .61
yperlipidemia 54 (707) 92 (1251) .001
istory of smoking 65 (860) 70 (952) .01
ulmonary disease 19 (246) 16 (210) .03
enal disease 15 (196) 14 (183) .30
ypertension 65 (855) 65 (886) .84
rior MI 51 (668) 53 (712) .36
ngina 91 (1196) 92 (1251) .19
revious coronary stent 4 (59) 8 (105) .002
revious PTCA 12 (153) 18 (238) .001
ysrhythmias 16 (211) 14 (191) .15
trial fibrillation 6 (83) 6 (82) .79
alvular disease 9 (124) 7 (93) .02
arotid disease 10 (136) 12 (161) .19
jection fraction  55% 63 (751) 65 (794) .80
jection fraction  44% 14 (181) 14 (184) .90
ongestive heart failure 29 (385) 29 (390) .81
ortic vascular disease 1 (8) 1 (13) .30
eripheral vascular disease 15 (201) 15 (197) .59
yncope 6 (79) 5 (74) .55
ransient ischemic attack 5 (71) 5 (69) .73
troke 6 (75) 6 (76) .95
astrointestinal disease 24 (320) 27 (365) .12
ematologic disease 4 (57) 3 (42) .09
epatic disease 8 (99) 7 (90) .36
reoperative medications
-Blockers 68 (889) 76 (1023) .001
Aspirin 60 (795) 67 (905) .001
IABP 1 (9) 0.5 (6) .41
Antiarrhythmics 10 (131) 10 (142) .65
ACE inhibitors 42 (556) 43 (577) .85
Ca2 channel blockers 35 (460) 39 (522) .05
Diuretics 25 (328) 21 (278) .007
Intravenous inotropes 5 (67) 2 (26) .001
Nonaspirin platelet inhibitors 1 (16) 1 (17) .93
Vasodilators 12 (156) 8 (107) .001
Warfarin or heparin 26 (338) 23 (311) .10
Antifibrinolytics 0.15 (2) 0.52 (7) .10
egion
Asia 13 (168) 5 (61) .001
Canada 6 (82) 8 (107) .09
Europe 43 (558) 36 (488) .001
Middle East 2 (22) 2 (24) .84
South America 6 (77) 4 (59) .08
United Kingdom 8 (103) 20 (268) .001
United States 23 (304) 26 (345) .15
ean  SEM. MI, Myocardial infarction; PTCA, percutaneous transluminal coronary angioplasty; IABP, intra-aortic balloon pump; ACE, angiotensin-
onverting enzyme.
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3arly cardiac mortality. Although randomized trials are still
eeded, these data suggest that preoperative statin therapy is
ssociated with a reduced risk of acute postoperative cardiac
urgical mortality. Moreover, discontinuation of statins after
ardiac surgery is associated with an increased risk of late
n-hospital mortality.
Figure 1. Univariate analysis of all-cause mortality,
infarction (MI). The incidence, associated odds ratios
cardiac mortality, and nonfatal, in-hospital MI in pati
ABLE 2. Intraoperative demographic variables and risk
atients not receiving preoperative antihyperlipidemic the
ntraoperative demographics and risk factors (%, [n]) No stat
rossclamp time (min)
otal bypass time (min)
rossclamp used  1 time
ide-biter clamp used  1 time
umber of CABGs  3
rterial filter used during CPB
embrane oxygenator
owest temperature actively cooled (C°)
ighest temperature actively warmed (C°)
entricular vent
ntraoperative intravenous inotropes
ntraoperative IABP
ntraoperative antifibrinolytics
eturn to CPB
ntraoperative VAD
ean  SEM. CABG, Coronary artery bypass graft; CPB, cardiopulmonarpatients who did not (n  1314) are shown. DOS, Day of su
96 The Journal of Thoracic and Cardiovascular Surgery ● AuguLong-term statin administration in ambulatory patients is
ssociated with a reduced risk of adverse cardiovascular
vents, including death, MI, stroke, atrial fibrillation, and
enal dysfunction.1-11 However, recent evidence sugges
hat statins may also reduce the risk of acute adverse out-
omes after invasive cardiovascular procedures.15,19-25 For
iac mortality, and nonfatal, in-hospital myocardial
95% confidence intervals (CI) of all-cause mortality,
receiving preoperative statin therapy (n  1352) and
rs in patients receiving preoperative statin therapy and
rapy (n  1314) Statin therapy (n  1352) P value
 0.71 58.4  0.72 .21
 0.96 93.5  0.97 .01
(29) 6 (82) .001
(274) 22 (288) .70
(967) 74 (1006) .63
(1048) 83 (1112) .07
(1262) 99 (1343) .001
 0.08 31.0  0.08 .32
 0.02 37.0  0.02 .003
(1210) 91 (1233) .41
(913) 71 (956) .49
(18) 1 (19) .94
(904) 72 (978) .15
(42) 3 (42) .89
(0) 1 (1) .999
ass; IABP, intra-aortic balloon pump; VAD, ventricular assist device.card
, and
entsfacto
rapy
in the
59.7
96.9
2
21
74
80
96
30.9
36.9
92
69
1
69
3
0rgery; POD, postoperative day.
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Collard et al Surgery for Acquired Cardiovascular Diseasexample, statin administration at the time of percutaneous
ransluminal coronary angioplasty is independently associ-
ted with improved 30-day and 6-month survival.7 Statin
se was also recently associated with a reduced risk of
erioperative mortality in patients undergoing vascular or
ardiac surgery.15,16 We now demonstrate that preoperati
tatin therapy is not only independently associated with a
educed risk of early cardiac mortality, but that discontinu-
tion of preoperative statin therapy in the immediate post-
perative period is also independently associated with an
ncreased risk of late in-hospital mortality after primary,
Figure 2. Multivariate analysis of early (DOS-POD3) all-
primary CABG surgery controlling for patient demogra
propensity score. Significant, independent predictors of
their associated odds ratios and 95% confidence interv
3 were cardiac in origin.lective CABG surgery. e
The Journal of ThoracicAlthough the exact mechanisms underlying the observed
ssociation of preoperative statin therapy with reduced car-
iac surgical mortality are unclear, accumulating evidence
uggests that statins exert multiple effects independent of
heir effect on LDL cholesterol.26-35 In patients with acut
oronary syndromes (ACS) or idiopathic dilated cardiomy-
pathy, statin therapy has been shown to improve ventric-
lar function and reduce markers of inflammation, including
-reactive protein, serum amyloid A, tumor necrosis factor ,
nterleukin 6, and brain natriuretic peptide levels.27-29 St-
tins have also been shown to be protective against isch-
e mortality (A) and cardiac mortality (B) after elective,
s, perioperative risk factors, medications, and statin
y all-cause mortality and cardiac mortality, along with
I) are shown. Note that all deaths between DOS-PODcaus
phic
earl
als (Cmia and reperfusion injury in the heart, lung, brain,
and Cardiovascular Surgery ● Volume 132, Number 2 397
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3idney, and gut.31-34,36 For example, simvastatin inhibite
eukocyte-endothelial cell interactions in an isolated, per-
used rat heart model, while preserving cardiac contractile
unction and coronary perfusion after myocardial ischemia
nd reperfusion.32 In addition to promoting systemic an-
xidant effects, statins have also been shown to modulate
emodeling of the cardiac extracellular matrix and to inhibit
ynthesis of isoprenoids required for the posttranslational
odification of important signaling molecules, such as Rho,
ac, and Ras.29,30 Multiple mechanisms, independent o
holesterol reduction, may thus underlie the protective in-
uence of preoperative statin therapy on acute cardiac sur-
Figure 3. Multivariate analysis of late (POD4-discharge)
CABG surgery controlling for the postoperative discontinu
converting enzyme inhibitor therapy. Significant, independ
along with their associated odds ratios and 95% confid
therapy independently predicted increased all-cause andical mortality.12-14 a
98 The Journal of Thoracic and Cardiovascular Surgery ● AuguDepending on the statin type, the half-life of inhibitory
ctivity for HMG-CoA reductase may range as high as 20
o 30 hours because of the contribution of active metabo-
ites. However, acute discontinuation of statins in ambula-
ory patients with ACS has been shown to increase the risk
f adverse cardiovascular outcomes. Heeschen and col-
eagues37 demonstrated in ambulatory patients experiencin
CS that administration of statin therapy before the onset of
ymptoms was associated with a reduced incidence of 30-
ay all-cause mortality and nonfatal MI compared with
onuse of statins (adjusted OR 0.49, 95% CI 0.21-0.86; P
004). Moreover, the incidence of 30-day all-cause mortality
use mortality (A) and cardiac mortality (B) after elective
of preoperative statin, aspirin, -blocker, or angiotensin-
redictors of late all-cause mortality and cardiac mortality
intervals (CI) are shown. Only discontinuation of statin
iac mortality occurring on or after POD 4.all-ca
ation
ent p
ence
cardnd nonfatal MI was significantly increased when statin
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Collard et al Surgery for Acquired Cardiovascular Diseaseherapy was withdrawn compared with when statin therapy
as continued (adjusted OR 2.93, 95% CI 1.64-6.27; P 
005). Both effects were independent of cholesterol levels,
urther supporting the non–lipid-mediated benefits of statin
herapy. Finally, statin therapy was shown to be less effec-
ive in reducing the risk of death or nonfatal MI when
nitiated after the presentation of an ACS, compared with
retreatment before the onset of symptoms (14% vs 51%
elative risk reduction). These results are consistent with
ur present findings in CABG surgical patients suggesting
hat postoperative discontinuation of statin therapy is asso-
iated with an increased risk of late, all-cause in-hospital
ortality.
Despite guidelines by the American College of Cardiol-
gy and American Heart Association recommending statins
or CABG patients with LDL concentrations greater than
00 mg/dL,38 two thirds of eligible candidates may not
eceiving statin therapy at discharge.39 Explanations for no
einitiating statin therapy after CABG surgery may include
atients’ decreased tolerance of oral medications secondary
o nausea and vomiting, transient renal dysfunction, con-
erns pertaining to hepatic toxicity or myositis, or failure of
he responsible physician to reimplement preoperative med-
cations. Educating physicians about the potential benefits
f continuing statin therapy throughout the perioperative
eriod may therefore be warranted.
Although this prospective cohort study extends the re-
ults of previous studies suggesting that preoperative statin
herapy may be beneficial after major cardiovascular sur-
ery,15,16,19,20 the present study is not without limitatio
espite the use of propensity scoring and multivariate re-
ression models to adjust for potential confounders that
ffect postoperative outcomes, immeasurable or unknown
actors may still exist. Physician bias may have influenced
atient selection, statin type, and dose. Indeed, randomized
linical trials of statin use in other settings such as ACS (eg,
he Myocardial Ischemia Reduction with Acute Cholesterol
owering [MIRACL] trial), while encouraging, have not
lways confirmed as marked a reduction in mortality as was
een in early observational studies.40,41 Nonetheless, an
ntensive lipid-lowering statin regimen was recently shown
o have greater protection against death and major cardio-
ascular events in ACS patients than a standard regim42
uggesting that such patients may further benefit from early
nd continued lowering of LDL cholesterol to levels sub-
tantially below current target levels. There thus remains a
eed for a prospective, randomized study to investigate the
nfluence of statins on adverse cardiac surgical outcomes
nd to determine which patients would benefit the most
rom perioperative statin therapy. Second, we were unable
o determine the influence of the duration of preoperative
tatin therapy on the risk of postoperative outcomes. Al-
hough the duration of preoperative statin therapy was not
The Journal of Thoraciceasured or controlled in the present study, previous studies
ave shown that statin therapy improves endothelial func-
ion and lowers serum inflammatory markers as early as 6 to
6 weeks.7,26,27,29 Finally, further study is needed to de-
ine the effect of postoperative statin administration in
atients not receiving preoperative statin therapy.
onclusion
reoperative statin therapy may reduce the risk of early
ardiac mortality after primary, elective CABG surgery
equiring CPB. Furthermore, discontinuation of statins after
ardiac surgery is associated with an increased risk of late
n-hospital mortality.
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he Ischemia Research and Education Foundation (IREF) is an
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linical investigators via observational studies and clinical trials
ddressing ischemic injury of the heart, brain, kidney, and
astrointestinal tract. IREF provided all funding for execution
f the study, collection of the data, and analysis and publication
f the findings. The Multicenter Study of Perioperative Ischemia
McSPI) Research Group, formed in 1988, is an association of 160
nternational medical centers located in 23 countries, organized
hrough, and supported by grants from, IREF.
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